<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          您現在的位置: > Language Tips > Audio & Video > Special Speed News  
           





            Once-daily pill could simplify HIV treatment
          [ 2006-02-06 15:57 ]


          I’m Steve Ember with the VOA Special English Health Report.


          Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
          Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

          But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

          Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

          They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

          Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

          In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

          Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

          GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

          The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

          They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

          There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

          Experts say more than forty million people around the world are living with H.I.V.

          This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

          Vocabulary

           

           

           
           
           




          主站蜘蛛池模板: 亚洲色欲色欲WWW在线丝| 69人妻精品中文字幕| 国产乱码一二三区精品| 男女啪啪高潮激烈免费版| 伊人久久大香线蕉aⅴ色| 无码人妻精品一区二区三区蜜桃 | 亚洲成a人片77777kkkk| 国产 麻豆 日韩 欧美 久久| 免费国产午夜理论片不卡| 四虎国产精品久久免费精品| 在线播放深夜精品三级| 2021国产v亚洲v天堂无码| 亚洲中文字幕综合小综合| 夜夜添无码试看一区二区三区| 亚洲日韩国产精品第一页一区| 窝窝午夜色视频国产精品破| 亚洲成av人片色午夜乱码| 国产最新进精品视频| 国产免费一级在线观看| 免费现黄频在线观看国产| 五月婷网站| 亚洲精品一区二区动漫| 热久久国产| 2021亚洲国产精品无码| 日韩精品无码专区免费播放| 亚洲激情av一区二区三区| 亚洲欧美激情四射在线日| 国产亚洲综合区成人国产| 又大又硬又爽免费视频| 综合在线 亚洲 成人 欧美| 91精品国产福利尤物免费| 国产日韩综合av在线| 91精品国产吴梦梦在线观看永久| 亚洲欧美成人a∨观看| 精品无码一区在线观看| аⅴ天堂 在线| 欧美XXXX黑人又粗又长| 色噜噜av男人的天堂| 丁香婷婷激情俺也去俺来也| 久久亚洲精精品中文字幕| 好吊妞人成视频在线观看|